We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

152 hedge funds and large institutions have $478M invested in Progenics Pharmaceuticals Inc in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 63 increasing their positions, 37 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 37

40% more capital invested

Capital invested by funds: $341M → $478M (+$137M)

14% more call options, than puts

Call options by funds: $12M | Put options by funds: $10.6M

0% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 21

1% less funds holding

Funds holding: 153 → 152 (-1)

Holders
152
Holders Change
-1
Holders Change %
-0.65%
% of All Funds
3.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
63
Reduced
37
Closed
21
Calls
$12M
Puts
$10.6M
Net Calls
+$1.46M
Net Calls Change
+$2.45M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$16M
2
PFC
Phocas Financial Corp
California
+$2.26M
3
EAM
Eagle Asset Management
Florida
+$2.06M
4
State Street
State Street
Massachusetts
+$2M
5
AAP
Ardsley Advisory Partners
Connecticut
+$1.99M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$5.62M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.55M
3
CCM
Cadence Capital Management
Massachusetts
-$1.55M
4
PA
Pinnacle Associates
New York
-$741K
5
LCM
Landscape Capital Management
New Jersey
-$514K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fuller & Thaler Asset Management
26
Fuller & Thaler Asset Management
California
$2.33M -$166K -24,900 -7%
Morgan Stanley
27
Morgan Stanley
New York
$2.31M +$475K +71,420 +30%
Fisher Asset Management
28
Fisher Asset Management
Washington
$2.27M – – –
Invesco
29
Invesco
Georgia
$2.2M +$699K +105,101 +55%
Allianz Asset Management
30
Allianz Asset Management
Germany
$1.75M +$236K +35,462 +18%
Goldman Sachs
31
Goldman Sachs
New York
$1.67M -$159K -23,963 -10%
TA
32
Teachers Advisors
New York
$1.63M +$2.49K +375 +0.2%
KBC Group
33
KBC Group
Belgium
$1.63M +$6.99K +1,051 +0.5%
HP
34
Hikari Power
Japan
$1.49M – – –
Wells Fargo
35
Wells Fargo
California
$1.35M -$225K -33,866 -16%
PPA
36
Parametric Portfolio Associates
Washington
$1.33M -$105K -15,825 -8%
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$1.32M +$166K +24,979 +16%
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$1.28M – – –
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$1.23M +$33.7K +5,074 +3%
PA
40
Perceptive Advisors
New York
$1.21M +$669K +100,650 +163%
Creative Planning
41
Creative Planning
Kansas
$1.18M +$110K +16,600 +12%
DZ Bank
42
DZ Bank
Germany
$1.16M +$1.03M +155,431 New
New York State Teachers Retirement System (NYSTRS)
43
New York State Teachers Retirement System (NYSTRS)
New York
$997K – – –
Legal & General Group
44
Legal & General Group
United Kingdom
$966K +$2.95K +443 +0.3%
BA
45
BKS Advisors
Michigan
$933K -$66.5K -10,000 -7%
Swiss National Bank
46
Swiss National Bank
Switzerland
$913K +$44.5K +6,700 +6%
Squarepoint
47
Squarepoint
New York
$888K +$330K +49,661 +72%
UBS Group
48
UBS Group
Switzerland
$880K +$766K +115,197 +4,046%
Prudential Financial
49
Prudential Financial
New Jersey
$853K +$12K +1,800 +2%
ERSOT
50
Employees Retirement System of Texas
Texas
$850K – – –
1
2
3 4 5

PGNX Hedge Fund Activity: Q1 2018 in Review

152 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2018, worth a combined $478M — up 40% from $341M a quarter earlier.

Fund positioning in PGNX was balanced in Q1 2018: 21 funds opened new positions, 21 closed out, 63 added to existing stakes and 37 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $16M. The largest seller was Baker Bros. Advisors, cutting an estimated $5.62M.

  • 152 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2018, down from 153 in Q4 2017.
  • Funds reported $478M of Progenics Pharmaceuticals Inc stock for Q1 2018, up 40% quarter-over-quarter.
  • 21 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2018 and 21 closed out, a net change of 0 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q1 2018 was Armistice Capital, an estimated $16M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q1 2018 was Baker Bros. Advisors, an estimated $5.62M sold.

Based on aggregated 13F filings for Q1 2018.